We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+13.81%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.53B
AUM Growth
+$567M
Cap. Flow
+$2.93M
Cap. Flow %
0.04%
Top 10 Hldgs %
36.11%
Holding
184
New
8
Increased
71
Reduced
51
Closed
13

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$20.9M
2
INCY icon
Incyte
INCY
+$16.3M
3
ISRG icon
Intuitive Surgical
ISRG
+$14.4M
4
DXCM icon
DexCom
DXCM
+$14.1M
5
CNC icon
Centene
CNC
+$13.5M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$40.9M
2
UNH icon
UnitedHealth
UNH
+$38.4M
3
ELV icon
Elevance Health
ELV
+$26.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$24M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$19M

Sector Composition

Rank Sector Weight
1 Healthcare 99.55%
2 Industrials 0.38%
3 Energy 0.03%
4 Communication Services 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KOS icon
126
Kosmos Energy
KOS
$1.56B
$2.02M 0.03%
318,300
– –
COR icon
127
Cencora
COR
$60.3B
$1.69M 0.02%
10,210
-1,700
-14% -$269K
ALKS icon
128
Alkermes
ALKS
$8.82B
$1.58M 0.02%
+35,500
New +$849K
KRYS icon
129
Krystal Biotech
KRYS
$9.88B
$1.45M 0.02%
18,300
– –
KRTX
130
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$1.43M 0.02%
+7,300
New +$1.57M
HZNP
131
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1.41M 0.02%
12,411
-289,439
-96% -$24M
RCUS icon
132
Arcus Biosciences
RCUS
$3.57B
$1.36M 0.02%
65,864
-17,636
-21% -$485K
VRDN icon
133
Viridian Therapeutics
VRDN
$2.13B
$1.35M 0.02%
46,100
– –
A icon
134
Agilent Technologies
A
$39.1B
$1.19M 0.02%
7,978
-649
-8% -$92.7K
MCK icon
135
McKesson
MCK
$98.5B
$1.1M 0.01%
2,920
-18
-0.6% -$6.71K
CELL
136
DELISTED
PhenomeX Inc. Common Stock
CELL
$1.03M 0.01%
385,014
– –
ISEE
137
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$895K 0.01%
+41,800
New +$892K
ARWR icon
138
Arrowhead Research
ARWR
$12.1B
$864K 0.01%
+21,300
New +$706K
DNLI icon
139
Denali Therapeutics
DNLI
$3.67B
$862K 0.01%
31,000
– –
CAH icon
140
Cardinal Health
CAH
$53.4B
$815K 0.01%
10,600
+9,682
+1,055% +$736K
SEER icon
141
Seer Inc
SEER
$108M
$790K 0.01%
136,133
– –
LH icon
142
Labcorp
LH
$24.3B
$784K 0.01%
3,876
-664
-15% -$130K
MRK icon
143
Merck
MRK
$324B
$749K 0.01%
6,751
+1,907
+39% +$195K
INBX
144
DELISTED
Inhibrx, Inc. Common Stock
INBX
$732K 0.01%
29,700
-13,800
-32% -$406K
RCKT icon
145
Rocket Pharmaceuticals
RCKT
$348M
$716K 0.01%
+36,600
New +$674K
MRUS
146
DELISTED
Merus
MRUS
$707K 0.01%
45,700
+20,300
+80% +$357K
SPY icon
147
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$688K 0.01%
1,800
– –
XNCR icon
148
Xencor
XNCR
$1.44B
$661K 0.01%
25,400
– –
NVCR icon
149
NovoCure
NVCR
$2.04B
$660K 0.01%
+9,000
New +$677K
GOOG icon
150
Alphabet (Google) Class C
GOOG
$3.9T
$532K 0.01%
6,000
– –
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2022 Portfolio in Review

As of Q4 2022, Bellevue Group held 184 positions worth $7.53B, up 8.1% from $6.97B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Bellevue Group's Q4 2022 filing shows 8 new, 71 increased, 51 reduced and 13 closed positions. Its largest new stake was Natera: 173,812 shares worth $6.98M. The largest sale was Abiomed Inc, an estimated $40.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q4 2022 buy was Natera: 173,812 shares worth $6.98M.
  • Bellevue Group added most to Fate Therapeutics in Q4 2022, an estimated $20.9M increase.
  • Bellevue Group's biggest Q4 2022 reduction was UnitedHealth, cutting an estimated $38.4M.
  • Bellevue Group fully exited Abiomed Inc in Q4 2022, selling an estimated $40.9M.
  • Bellevue Group's ten largest holdings make up 36% of its $7.53B portfolio in Q4 2022.
  • Bellevue Group opened 8 new positions and closed 13 in Q4 2022.
  • Bellevue Group's portfolio value rose 8.1% quarter-over-quarter to $7.53B.

Based on Bellevue Group's 13F filing for Q4 2022, filed 14 Feb 2023.